Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, Roberts S, Ingleson E, Bowles K, Garg M, Lokare A, Messiou C, Houlston RS, Jackson G, Cook G, Pratt G, Owen RG, Drayson MT, Brown SR, Jenner MW. Kaiser MF, et al. Among authors: walker k. J Clin Oncol. 2023 Aug 10;41(23):3945-3955. doi: 10.1200/JCO.22.02567. Epub 2023 Jun 14. J Clin Oncol. 2023. PMID: 37315268
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Hinsley S, Walker K, Sherratt D, Bailey L, Reed S, Flanagan L, McKee S, Brudenell Straw F, Dawkins B, Meads D, Auner HW, Kaiser MF, Cook M, Brown S, Cook G; Myeloma UK Clinical Trials Network. Hinsley S, et al. Among authors: walker k. Trials. 2020 Oct 2;21(1):826. doi: 10.1186/s13063-020-04739-8. Trials. 2020. PMID: 33008427 Free PMC article.
MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.
Brown S, Sherratt D, Hinsley S, Flanagan L, Roberts S, Walker K, Hall A, Pratt G, Messiou C, Jenner M, Kaiser M; Myeloma UK Early Phase Clinical Trial Network. Brown S, et al. Among authors: walker k. BMJ Open. 2021 Mar 24;11(3):e046225. doi: 10.1136/bmjopen-2020-046225. BMJ Open. 2021. PMID: 33762245 Free PMC article.
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, Franks KN, Gilbert A, Hanna GG, Hannaway N, Harrow S, Haswell T, Hiley CT, Hinsley S, Krebs M, Murden G, Phillip R, Ryan AJ, Salem A, Sebag-Montefoire D, Shaw P, Twelves CJ, Walker K, Young RJ, Faivre-Finn C, Greystoke A. Walls GM, et al. Among authors: walker k. Clin Transl Radiat Oncol. 2020 Sep 22;25:61-66. doi: 10.1016/j.ctro.2020.09.006. eCollection 2020 Nov. Clin Transl Radiat Oncol. 2020. PMID: 33072895 Free PMC article.
Online Symptom Monitoring During Pelvic Radiation Therapy: Randomized Pilot Trial of the eRAPID Intervention.
Holch P, Absolom KL, Henry AM, Walker K, Gibson A, Hudson E, Rogers Z, Holmes M, Peacock R, Pini S, Gilbert A, Davidson S, Routledge J, Murphy A, Franks K, Hulme C, Hewison J, Morris C, McParland L, Brown J, Velikova G. Holch P, et al. Among authors: walker k. Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):664-676. doi: 10.1016/j.ijrobp.2022.09.078. Epub 2022 Oct 12. Int J Radiat Oncol Biol Phys. 2023. PMID: 36241128 Free article. Clinical Trial.
Assessment of MR blood-oxygen-level-dependent (BOLD) cerebrovascular reactivity under general anesthesia in children with moyamoya.
Choi EJ, Levin D, Robertson A, Kirkham FJ, Muthusami P, Krishnan P, Shroff M, Moharir M, Dirks P, MacGregor D, Pulcine E, Bhathal I, Kassner A, Walker K, Allan W, deVeber G, Logan WJ, Dlamini N. Choi EJ, et al. Among authors: walker k. Pediatr Radiol. 2024 May 23. doi: 10.1007/s00247-024-05930-8. Online ahead of print. Pediatr Radiol. 2024. PMID: 38777883
Structure-Activity Relationships, Deuteration, and Fluorination of Synthetic Cannabinoid Receptor Agonists Related to AKB48, 5F-AKB-48, and AFUBIATA.
Sparkes E, Maloney CJ, Markham JW, Dane C, Boyd R, Gilchrist J, Moir M, Gordon R, Luo JL, Pike E, Walker KA, Kassiou M, McGregor IS, Kevin RC, Hibbs DE, Jorgensen WT, Banister SD, Cairns EA, Ametovski A. Sparkes E, et al. Among authors: walker ka. ACS Chem Neurosci. 2024 May 20. doi: 10.1021/acschemneuro.3c00850. Online ahead of print. ACS Chem Neurosci. 2024. PMID: 38766866
2,428 results